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Abstract
This study was designed to develop a risk assessment chart for the clinical management
and prevention of the risk of cardiovascular disease (CVD) in Iranian population, which is
vital for developing national prevention programs. The Isfahan Cohort Study (ICS) is a popu-
lation-based prospective study of 6504 Iranian adults35 years old, followed-up for ten
years, from 2001 to 2010. Behavioral and cardiometabolic risk factors were examined every
five years, while biennial follow-ups for the occurrence of the events was performed by
phone calls or by verbal autopsy. Among these participants, 5432 (2784 women, 51.3%)
were CVD free at baseline examination and had at least one follow-up. Cox proportional
hazard regression was used to predict the risk of ischemic CVD events, including sudden
cardiac death due to unstable angina, myocardial infarction, and stroke. The model fit statis-
tics such as area under the receiver-operating characteristic (AUROC), calibration chi-
square and the overall bias were used to assess the model performance. We also tested the
Framingham model for comparison. Seven hundred and five CVD events occurred during
49452.8 person-years of follow-up. The event probabilities were calculated and presented
color-coded on each gender-specific PARS chart. The AUROC and Harrell’s C indices were
0.74 (95% CI, 0.72–0.76) and 0.73, respectively. In the calibration, the Nam-D’Agostino χ2
was 10.82 (p = 0.29). The overall bias of the proposed model was 95.60%. PARS model
was also internally validated using cross-validation. The Android app and the Web-based
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risk assessment tool were also developed as to have an impact on public health. In compari-
son, the refitted and recalibrated Framingham models, estimated the CVD incidence with
the overall bias of 149.60% and 128.23% for men, and 222.70% and 176.07% for women,
respectively. In conclusion, the PARS risk assessment chart is a simple, accurate, and well-
calibrated tool for predicting a 10-year risk of CVD occurrence in Iranian population and can
be used in an attempt to develop national guidelines for the CVD management.
Introduction
Recent guidelines on the primary prevention of cardiovascular disease (CVD) in clinical prac-
tice stress the urgency of having a necessary preventive intervention procedure regarding the
absolute risk of CVD rather than assessment of any particular risk factors such as blood pres-
sure and/or cholesterol levels [1]. Indeed, researchers have started to believe that hypertension
is not a proper term to use. Also, the term “risk” should be applied instead of “risk factors” by
the future Clinicians [2, 3]. However, most cardiovascular risk factors cannot be categorized
based on the presence or absence of the risk, mostly synergistic effects of the risk factors should
be considered; there is no absolute risk and the effects of the risk factors are proportional. Data
from a North American study evaluating Clinicians’ ability to quantify CVD risk and treat-
ment benefits, recommends that both general practitioners and specialist physicians substan-
tially overestimate the CVD risk and benefits of treatment [4]. As a result, the statistical
prediction of future cardiovascular events has received increased attention in recent years.
Several well-known models and charts of CVD risk assessment have been developed and
updated in the past five decades, including the Framingham risk score [5], the pooled cohort
equations recommended by the American College of Cardiology (ACC) in 2013, American
Heart Association (AHA) cardiovascular risk-assessment guidelines [1], and the SCORE [6],
ASSIGN [7], Q-Risk [8], PROCAM [9] and Globorisk [10, 11] risk prediction models. A grow-
ing body of evidence indicates that risk prediction scores lead to improvement in risk manage-
ment [2]. However, the constitution of risk chart is based on the risk factors outline, which is
distinct in different populations. Consequently, the risk assessment charts are specific for each
population and cannot be used in different populations [12]. Hence, the design of specific
risk-assessment models for different populations depends on parameters measured from the
local population and this seems necessary for optimizing the risk assessment for individuals
within the specific population [12].
On the report of the World Health Organization, the Middle Eastern countries are antici-
pated to have the highest incidence of diabetes, and in case of CVD till 2020 [13, 14]. As one of
the Middle Eastern countries, Iran has alarming incidence rates of CVD and the associated
risk factors [15, 16]. However, there are small data from longitudinal studies, assessing the
impact of CVD risk factors among Iranian population, limited to specific areas [17]. To the
best of our knowledge, no CVD risk prediction score has been specifically developed for the
Iranian population to date, which is vital for developing national CVD management and pre-
vention programs. Given the importance of developing local risk assessment tools, we used the
Isfahan cohort study (ICS) dataset [14], a 10-year population-based longitudinal study started
in 2001 with the main goal of developing the Persian Atherosclerotic cardiovascular disease
Risk Stratification (PARS) charts in Iran. The study was performed by Isfahan Cardiovascular
Research Center (ICRC), a WHO-collaborating center (http://apps.who.int/whocc/Detail.
aspx?cc_ref=IRA-23&cc_code=ira).
PARS risk assessment charts
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Materials and methods
Study population
The ICS is a longitudinal population-based study, with 6504 adult subjects aged35 years at
the baseline examination, enrolled in 2001 using multistage random cluster sampling [18].
The subjects living in three Iranian central areas (Arak, Isfahan, and Najafabad), enrolled in
the Isfahan Healthy Heart Program (IHHP), were recruited for ICS [14, 19]. The IHHP design
was previously reported [20]. Isfahan is a city with a population of 1986542, the second most
populous metropolitan area in Iran after Tehran. In 2006, the population of Arak and Najafa-
bad, was 555975 and 282430, respectively. These areas were selected because of the socioeco-
nomic, demographic picture and health profile similarities to the other large cities in Iran. The
overall prevalence of CVD was estimated as 19.4% in Isfahan [21], which was almost similar to
that of Tehran, the capital of Iran (21.8%) [22].
Participants were recruited from 2001 and followed-up for at least ten years. All subjects
signed the informed consent form for the experimental procedure. Ethics approval was
obtained from the Isfahan Cardiovascular Research Center Ethics Committee, a WHO collab-
orating center in the Eastern Mediterranean Region (EMR), and Isfahan University of Medical
Sciences and conformed to the Declaration of Helsinki. For controlling selection bias, the sam-
ples were randomly selected from a healthy population. The participants were selected by mul-
tistage random cluster sampling. The study population was first stratified by their living area
(urban vs rural). We then randomly selected census blocks from each county and divided
them into clusters. Within each cluster, households were randomly selected for enumeration.
From each household, we randomly selected one eligible individual. The inclusion criteria
were as follows: being Iranian, aged 19 years, mentally competent, and not pregnant. The
exclusion criteria were: having a stroke, ischemic heart attack, coronary heart disease, and
heart failure.
Meanwhile, the random sampling was used without any restriction for the elderly, as to
overcome underestimation or volunteer bias [16]. These subjects were followed up until CVDs
occurred. All participants had no clinical history of chronic diseases and were interviewed by
trained personnel (registered Nurses, Dietitians and General Practitioners), using standard
questionnaires assessing lifestyle habits, various sociodemographic predictors, and clinical or
biological characteristics. They were followed up by repeating these measurements every five
years, and biennially by phone calls looking for the occurrence of any of primary or secondary
events. However, as it happens in cohort studies, there were lost to follow-up participants in
each of these follow-up phases (Fig 1). An important reason for the loss to follow-up was a
change in phone numbers, based on the government new policy in the whole country. It was
part of a network capacity expansion policy, without any particular distribution. It was thus
completely random, not biasing the follow-up [14].
Risk factor measurements
Participants were interviewed by trained personnel to complete standardized questionnaires,
including questions on cardiovascular risk factors, and also clinical examinations, electrocardi-
ography and laboratory evaluation [19].
After sitting for five minutes, trained physicians measured the blood pressure by standard
mercury Sphygmomanometers, using the right arm of resting participants. Blood pressure
measurements were repeated after 15 minutes, and the average of two measures was reported.
While shoes were removed, height was measured to the closest centimeter by a trained techni-
cian. A calibrated scale was used to measure weight in light clothing. Weight (kg) was divided
PARS risk assessment charts
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by height in squared meter (m2), and represented as body mass index (BMI). The smallest cir-
cumference at or below the costal margin was taken as waist circumference (WC). The hip cir-
cumference was taken at the level of the greater trochanter.
Fasting (12 h) blood samples (FBS) were taken from the participants. The entire samples
were frozen at −20˚C, in order to be assayed within 72 hours at the central laboratory of the
Fig 1. The flowchart of inclusion and lost to follow-up of ICS cohort participants.
https://doi.org/10.1371/journal.pone.0189389.g001
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ICRC, meeting the criteria of the WHO-collaborating center. Moreover, it was under the
external quality control of St. Rafael University, Leuven and Belgium [18]. A 2-hour post-load
plasma glucose (2 hpp) test was performed, using the samples from entire participants, without
including diabetic subjects. DNA samples and serums were frozen at -70˚C, for further
analysis.
A cell counter AL820 was used to measure hematological parameters. An auto-analyzer
(Eppendorf, Hamburg, Germany) was used to enzymatically measure total serum cholesterol
(TC), triglycerides (TG) and FBS. In subjects with TG <400 mg/dl, the Friedewald equation
was used to calculate serum low-density lipoprotein cholesterol (LDL-C), and in other cases,
standard kits’ instructions were followed. Low-density and very low-density lipoproteins were
precipitated, using dextran sulfate-magnesium, and then serum high-density lipoprotein-cho-
lesterol (HDL-C) was measured [21].
Event criteria
Since 2001, each participant has been followed up for every two years. In 2007, full structured
interview, clinical and blood-sample testing were repeated as the baseline examination. Tele-
phone interviews were implemented in 2003, 2005, 2007, 2009 and 2011 and if they were
deceased, attempts were made to contact all living participants or their first-degree relatives.
When the phone interviews were unsuccessful, the participants were visited at their home
address for the follow-up. Structured questionnaire was asked based on being alive, hospital-
ized and experiencing specific neurological symptoms. The date of death, hospitalization or
neurological symptoms, physician diagnosis and the hospital’s name were obtained during the
interview [14]. For deaths out of hospital, death registries from the provincial mortality data-
base were used to obtain death certificates. Verbal autopsies were performed before death by a
trained Nurse based on predefined questionnaire, including medical history, signs and symp-
toms. Additional secondary interviews for hospitalized cases were performed where informa-
tion was incomplete or inconsistent.
When there were not any inconsistent dates or diagnosis, or the records were not obtain-
able, we used the original medical records of MI and stroke registry database of the Surveil-
lance Department of ICRC, to verify the reported events. If we were not able to find
hospitalization data in the database, trained Nurses investigated the medical records [14].
A professional panel, consisting of Cardiologists and Neurologists have reviewed all the
documents and made a decision about the diagnosis of each CVD event. Such events were
defined as either acute coronary syndromes, consisting of fatal or non-fatal myocardial infarc-
tion and unstable angina, sudden cardiac death, and fatal or non-fatal stroke. The detailed
description of the above-mentioned end points, risk factor measurements, and data collection
have been provided in the previous reports [14, 15, 19].
Statistical methods
CVD risk function. The development of the risk function in ICS was assessed, according
to the following three steps: I) Refitted Framingham function: multiple Cox (proportional-haz-
ards) regression models were derived, using the same variables of Framingham equation and
ICS database. II) Recalibration of Framingham function: in these functions, the β coefficients
were taken from the Framingham model, but the mean values and the incidence rates of the
risk factors were taken from the ICS cohort. III) PARS function, i.e. the proposed new model
in this study [5]. The regression models were first fitted one-at-a-time to a broad set of risk fac-
tors separately, including age, sex, TC, TG, systolic blood pressure (SBP), diastolic blood pres-
sure (DBP), HDL-C, LDL-C, TC\HDL-C ratio, LDL-C\HDL-C ratio, TC\TG ratio, LDL-C\TG
PARS risk assessment charts
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ratio, BMI, waist to hip ratio (WHR), WC, smoking status and diabetes. The most important
risk factors were then hierarchically included in the model based on the higher hazard ratio
(HR). At each step, significant risk factors remained in the model. The final model, referred to
PARS risk function, had the best discrimination and calibration (The protocol: dx.doi.org/10.
17504/protocols.io.j7rcrm6).
After testing the assumption of proportionality, cox proportional hazards model was used.
The Schoenfeld residuals were used for testing the proportional hazards (PH) assumption for
risk factors. Further evaluation was applied to check the PH assumption, regarding the risk
factors plotted graphically with the log-cumulative hazard plots as a function of survival time,
comparing Kaplan-Meier survival estimates and Cox adjusted estimates plotted on the same
graph. If the graphical approaches suggested that there is some violation of PH assumption, an
extended cox model was run based on an appropriate function of survival time. It was per-
formed by defining the product term involving time-independent variable with some function
of time (g(t) or Heaviside function) and testing the coefficient of the product term. In our anal-
ysis, there was no significant coefficient of the time-dependent variable based on product
terms.
The Cox regression model was used to estimate the absolute 10-year risk of CVD (P) as fol-
lows:
P ¼ 1   SðtÞexp½f ðx;MÞ
f ðx;MÞ ¼
XN
i¼1
biðxi   MiÞ
8
>
<
>
:
ð1Þ
where S(t) is the survival rate calculated at the mean risk factor values, Mi are the mean risk
factor values in the ICS, βi are the regression coefficients, xi represents risk factors and N is the
number of compartments in the model.
Model performance assessment. A two-tailed z statistic was used to compare the hazard
ratios in the ICS and Framingham functions [22, 23], in which z = (bF − bI)/SE(bF − bI) and
SEðbF   bIÞ ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
SE2bF þ SE
2
bI
q
, where bF and bI are the β coefficient of the Framingham and ICS
model, respectively with SEbF and SEbI , as the standard errors (SEs) of bF and bI.
The degree of discrimination power of the model was assessed, using AUROC or C-statistic
and Harrell’s C. The Nam-D’Agostino chi-square test was used for evaluating time-to-event
analysis calibration [24].
Validation procedures. Two internal validation (resampling) methods namely as 10-fold
cross-validation and bootstrapping were used to obtain unbiased estimates of predictive accu-
racy. The above two techniques are used to assess, if the developed risk scores could be general-
ized to an independent data set. In this method, the data set is randomly divided into ten equal
size groups. Among which, the model is tested on a single validation group, while the model is
estimated, using the other nine groups (training data). Such validation is then repeated ten
times, in which each of the groups is used one time, for validation. Then the average of ten val-
idations was calculated. Moreover, internal bootstrapping was used to obtain unbiased esti-
mates of predictive accuracy. Fifty thousand random samples were bootstrapped. Finally,
overall bias in predicting CVD incidence was estimated as [13, 25]:
overall biasð%Þ ¼
Predicted incidence   Observed incidence
observed incidence
 
 100 ð2Þ
We applied a risk threshold, people with risk higher than 20% were considered high risk by
recent guidelines [1, 26–28].
PARS risk assessment charts
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Risk chart. We constructed 10-year risk assessment charts of CVD incidence, using
important risk factors. Such a user-friendly chart included SBP, WHR, diabetes, smoking sta-
tus, CVD family history and TC. SBP was grouped into four classes: (1)<120, (2) 120–139, (3)
140–159, and (4)160 mm Hg. These cutoff points were based on National Cholesterol Edu-
cation Program’s Adult Treatment Panel III (ATP III). TC was categorized into five groups:
(1)<150, (2) 150–200, (3) 200–250, (4) 250–300 and (5)300 mg/dl. High waist-to-hip ratio
(WHR) was defined as WHR 0.80 and 0.95 in women and men, respectively. When FBS
126 mg/dl or the 2h post-load plasma glucose200 mg/dl or the patient was receiving anti-
diabetic agents, the subject were diagnosed with diabetes mellitus. The smoking variable com-
prised of current smokers.
The following CVD probabilities ( 1%, 2%, 3%–4%, 5%–9%, 10%–14% and15%) were
displayed on the risk chart and color-coded.
Statistical modeling and analysis were performed, using SAS software, version 9.3 (SAS
Institute Inc). Matlab version 8.6 (The MathWorks Inc., Natick, MA, USA) was used for risk
chart generation and model validations.
Our missing data were missing at random (MAR). We thus used multivariate imputation
by a chained equation’s method in STATA 12.0 for managing the measurements with missing
data. The baseline characteristics and the prevalence of CVD risk factors were compared,
among lost to follow-up and loyal subjects, using the sensitivity analysis. Participants without
any event and loss to follow-up events were considered as censored.
Results
The response rate of house interview was 98%, but only 95% attended the examination clinic.
The main reasons for not participating were related to address and or phone number change,
and to a less extent, not willing to take part in multiple follow-ups. There were 181 (2.8%)
cases with CVD events excluded from the ICS baseline examination. A number of 891 (14.1%)
participants were missed before the first follow-up. The loss to follow-up rate was 404 (6.4%),
249 (3.9%), 87 (1.4%) and 104 (1.6%) in the second through the fifth stage of follow-ups,
respectively (Fig 1). The prevalence of the CVD risk factors and also baseline characteristics
were not significantly different between lost to follow-ups and loyal subjects [14, 16].
Baseline risk factors
The Baseline examination of participant risk factors is shown in Table 1. The Average age for
men and women was 51.2±11.9 and 50.3±11.3 years, respectively. The majority of women
have a high WHR (94.6%). In comparison with women, the smoking rate was far greater in
men (41.6% vs. 3.3%). The SBP level has almost similar frequency distribution in men and
women. Higher levels of TC were more prevalent in women, compared to men. The preva-
lence of diabetes mellitus was less in men, compared with women (9.3 vs. 12.6).
Cardiovascular events
A total of 705 CVD events (564 IHDs, 141 strokes) occurred, during 49452.8 follow-ups per-
son-years (minimum 0.1, maximum 12, median 10.9 years). IHD comprised of 39 (20 women
and 19 men) fatal and 113 (36 women and 77 men) non-fatal MI, 331 (171 women and 160
men) UA, and 81 (26 women and 55 men) sudden cardiac deaths. Ischemic stroke composed
of 30 (16 women and 14 men) fatal and 111 cases (57 women and 54 men) of non-fatal stroke.
The total CVD event rates were 1.6 per 100 person-year for men and 1.3 per 100 person-year
for women, without adjusting for age. Follow-up person-years, CVD events, and the levels of
risk factors of the baseline examination are shown in Table 2.
PARS risk assessment charts
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Refitted and recalibration of Framingham function
The CVD risk factor regression coefficients and HRs were estimated from sex-specific ICS
regression models, using the same variables as those in the Framingham function (Table 3).
During the discriminatory analysis, the AUROC was 0.730(95% CI, 0.703–0.757) and 0.754
Table 1. Baseline characteristics of the study participants, ICS, 2001–2011.
Men (N = 2648) Women (N = 2784)
Risk factors % %
High waist to hip ratioa 39.2 94.6
Systolic blood pressure(mm/Hg)
<120 44.4 44.9
120–139 37.1 33.7
140–159 12 13.4
>=160 6.6 8
Total cholesterol (mg/dl)
<150 11.4 7.5
150–200 35 30.4
200–250 34.1 36.4
250–300 14.2 18.6
>300 5.2 7.2
Diabetes 9.3 12.6
Smoker 41.6 3.3
Family history of CVD 5 5.7
Age (years) (Mean±SD) 51.15±11.93 50.27±11.32
CVD: cardiovascular disease; SD: standard deviation.
a Waist-to-hip ratio (WHR) 0.80 in women and 0.95 in men was considered as a high WHR.
https://doi.org/10.1371/journal.pone.0189389.t001
Table 2. Person-years of follow-up and CVD events according to risk factors in men and women, ICS, 2001–2011.
Men Women
Person-years of follow-up CVD events Person-years of follow-up CVD events
Total 23931 379 25522 326
High waist to hip ratio a 9190.1 214 24037.4 314
Systolic blood pressure (mm/Hg)
<120 11132.3 96 11652 67
120–139 8741.5 148 8746.2 116
140–159 2683 76 3347.7 78
>=160 1374.1 59 1776.1 65
Total cholesterol (mg/dl)
<150 2826.4 27 1917 15
150–200 8507.1 112 7938.5 71
200–250 8144.3 131 9206.3 123
250–300 3253.8 79 4710.25 77
>300 1198.9 30 1749.8 40
Diabetes 2059.8 82 3040.7 87
Smoker 9809.1 159 805.3 18
Family history of CVD 1205.7 22 1415.8 27
CVD: cardiovascular disease
a Waist-to-hip ratio (WHR) 0.95 in men and 0.8 in women was considered as a high WHR.
https://doi.org/10.1371/journal.pone.0189389.t002
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(95% CI, 0.727–0.781), for men and women, respectively. In the calibration, the Nam-D’Agos-
tino χ2 was 24.29 (p = 0.004) and 7.28 (p = 0.61) for men and women, respectively. The ICS
refitted Framingham model significantly overestimated the CVD incidence with the overall
bias of 149.60% and 222.70% in men and women, respectively. The 10-fold cross-validation
yielded a mean AUROC of 0.73 (95% CI, 0.70–0.76) and 0.75 (95% CI, 0.73–0.78) in men and
women, respectively.
The C statistic value for the recalibrated Framingham function applied to ICS was 0.700
(95% CI, 0.671–0.729) and 0.748 (95% CI, 0.721–0.775) for CVD prediction in men and
women, respectively. The value of χ2 was 6.23 (p = 0.62) and 12.19 (p = 0.14) for men and
women, respectively. The recalibrated Framingham model overestimated the CVD incidence
with the overall bias of 128.23% and 176.07% in men and women, respectively. The 10-fold
cross-validation, yielded a mean AUROC of 0.70 (95% CI, 0.67–0.73) and 0.75 (95% CI, 0.72–
0.77) in men and women, respectively.
PARS risk function
Having considered the variety of predictors and their interactions in a multivariate Cox regres-
sion, significant predictors of CVD events were age, sex, high WHR, SBP level, TC level, diabe-
tes mellitus, smoking status and family history of CVD. The optimal PARS model is presented
in Table 4.
The value of AUROC was 0.74 (95% confidence interval [CI], 0.72–0.76) and Harrell’s C
was 0.73. In the calibration, the Nam-D’Agostino χ2 was 10.82 (p = 0.29). Thus, what was pre-
dicted by PARS functions was similar to the actual ICS CVD rates (Fig 2). A number of 21
evaluated risk assessment models were also shown in S1 Supporting information among
which, the proposed model (Table 4) has the best goodness-of-fit in terms of the Nam-D’Agos-
tino χ2 and AUROC.
Table 3. Comparison of relative risk and performance of ICS and Framingham.
ICS cohort Framingham cohort
Women Hazard Ratio(95% CIs) Hazard Ratio(95% CIs) p
Log of age 180.05(47.45–683.21) 10.27(5.65–18.64) 0.0002
Log of total cholesterol 3.26(1.02–10.38) 3.35(2.00–5.62) 0.968
Log of HDL cholesterol 0.33(0.10–1.07) 0.49(0.35–0.69) 0.516
Log of SBP if not treated 57.76(9.97–334.44) 15.82(7.86–31.87) 0.18
Log of SBP if treated 70.47(10.77–464.87) 16.82(8.46–33.46) 0.136
Smoking 1.53(0.95–2.47) 1.70(1.40–2.06) 0.697
Diabetes 1.87(1.45–2.40) 2.00(1.49–2.67) 0.734
C statistics = 0.754 (95% CI, 0.727–0.781)
χ2 = 7.84(p = 0.55)
C statistics = 0.793 (95% CI, 0.772–0.814)
χ2 = 7.79 (p = 0.56)
Men Log of age 92.37 (27.69–308.21) 21.35(14.03–32.48) 0.024
Log of total cholesterol 6.20(2.36–16.27) 3.08(2.05–4.62) 0.190
Log of HDL cholesterol 0.48(0.16–1.44) 0.39(0.30–0.52) 0.726
Log of SBP if not treated 29.08(5.58–151.54) 6.91(3.91–12.20) 0.107
Log of SBP if treated 34.32(5.72–205.92) 7.38(4.22–12.92) 0.085
Smoking 1.28(1.04–1.57) 1.92(1.65–2.24) 0.002
Diabetes 1.84(1.42–2.38) 1.78(1.43–2.20) 0.834
C statistics = 0.730(95% CI, 0.703–0.757)
χ2 = 20.05 (p = 0.02)
C statistics = 0.763 (95% CI, 0.746–0.780)
χ2 = 13.48 (p = 0.14)
https://doi.org/10.1371/journal.pone.0189389.t003
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The 10-fold cross-validation, yielded a mean AUROC of 0.74 (95% CI; 0.72–0.76). In boot-
strap validation, the mean AUROC was 0.74 (min-max; 0.70–0.78). Accordingly, PARS model
could be internally validated. Moreover, the overall bias of the proposed model was 95.60%.
PARS risk assessment charts were then created (Figs 3–6).
Table 4. Adjusted HRs for CVD risk factors using PARS risk function, ICS, 2001–2011.
Risk factors Estimate Hazard Ratio 95% CI
Age 0.03759 1.038 1.031–1.045
Male 0.28957 1.335 1.111–1.508
Total cholesterol
<150a - -
150–200 0.20759 1.231 0.879–1.723
200–250 0.34201 1.408 1.013–1.957
250–300 0.45316 1.573 1.113–2.225
>300 0.54847 1.731 1.172–2.556
Systolic blood pressure
<120a - -
120–139 0.45643 1.578 1.291–1.929
140–159 0.73697 2.09 1.651–2.644
>=160 1.0467 2.848 2.207–3.676
Diabetes 0.63041 1.878 1.570–2.247
High waist to hip ratiob 0.26989 1.31 1.072–1.601
Family history of CVD 0.40182 1.495 1.116–2.002
Smoking 0.28974 1.336 1.104–1.617
CI, confidence interval;
a reference category
b Waist-to-hip ratio (WHR) 0.80 in women and 0.95 in men was considered as a high WHR.
https://doi.org/10.1371/journal.pone.0189389.t004
Fig 2. Comparison between observed and estimated 10-year risk of CVD using the PARS risk
function.
https://doi.org/10.1371/journal.pone.0189389.g002
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For instance, the estimated 10-year absolute CVD risk for a non-diabetic, non-smoker man
aged 45 years, with high WHR, SBP of 145 mm Hg, TC of 205 mg/dl, and a positive family his-
tory of CVD would be 6%, as shown by the light red color (Fig 6).
Discussion
ICS is the first longitudinal population-based study, primarily designed to develop a CVD risk
assessment tool (PARS), in Iran and EMR. ICS is being organized in three geographic areas
with a large urban and rural population [14]. We developed the PARS, as a new CVD risk pre-
diction tool in Iran, in preparation for a major change in national policy, by identifying the
patients at high risk of CVD.
Framingham prediction algorithms have been comprehensively used, in the United States
and other countries [29–31]. However, white middle class subjects were considered in such
studies. Thus, the generalized findings could not be applied, in principle, to other low- and
middle-income countries [14]. Such limitations of the Framingham risk function in diverse
populations were well-documented. The Framingham scores had overestimated risk in the
number of populations [6, 32–34]. Consistently, our result also indicated that Framingham
function overestimated risks in ICS population. We also found out that the ICS refitted and
recalibrated Framingham were not so different in the prediction of CVD events. Also, central
Fig 3. PARS charts for prediction of 10-year risk of fatal and non-fatal cardiovascular disease in ICS population with lower WHR
and no CVD family history, 2001–2011.
https://doi.org/10.1371/journal.pone.0189389.g003
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obesity and family history of CVD are independent risk factors for CVD events in the ICS pop-
ulation, which can be used as additive covariates, improving the model; a better calibration
was found in the model.
Recently, Globorisk models, a pooled analysis of prospective cohorts and health study in
different countries, in which a study from IRAN was used for validation, was introduced in the
literature [10, 11]. In Globorisk models, no risk chart was provided for IRAN, and the national
study used by the authors only included participants aged65 years. Thus, it was not included
for comparison.
Our method estimated the total CV event risk rather than the risk of CHD and/or stroke
alone, not consistent with the earlier version of the Framingham risk score and the risk predic-
tion models, originated from China [23], India [35], Turkey [36], Israel [37], Singapore [38],
South Korea [39], and Chile [40]. As the aforementioned models were restricted to risk of
coronary heart disease (CHD) [12] and also the PROCAM score [9], not consistent with our
model, calculate the risk of CHD and stroke, separately. By calculating total CV risk, including
the 10-year risk of fatal or non-fatal myocardial infarction, unstable angina, sudden cardiac
death, and fatal or non-fatal stroke, we anticipate to provide a better risk estimate. Accord-
ingly, WHO and current stress practice guidelines prefer to consider the total risk in making
decisions about treatments [1, 26, 41, 42].
Fig 4. PARS charts for prediction of 10-year risk of fatal and non-fatal cardiovascular disease in ICS population with higher WHR
and no CVD family history, 2001–2011.
https://doi.org/10.1371/journal.pone.0189389.g004
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Based on a large Iranian representative population, we created a PARS chart. The PARS
charts are user-friendly and color-coded (Figs 3–6). Furthermore, using a 6-color gradient
from brown as the highest risk, to green as the lowest probability of CVD event, which help
not only the Physicians but also the individuals to see their position on the chart [43].
It is known that diabetes is positively associated with the CVD risk. One of the limitations
of the Framingham risk score is the small number of diabetic people in a cohort of 5573 indi-
viduals (4%) and also the diabetes definition was based on a random blood glucose concentra-
tion >9 mmol/l or the use of anti-glycemic treatment. Hence, the accuracy of the Framingham
risk score for CV risk assessment in diabetic patients has been addressed in previous studies
[44]. The most widely used risk score in the European countries, SCORE [6], also lacks the
risk prediction power of diabetes because of the unavailability of data on diabetes, from some
cohorts and also due to non-uniform definitions of diabetes, among other cohorts of the Euro-
pean population. In our new risk assessment charts for Iranian population, diabetes is a critical
classifying risk factor due to being positioned, among the risk factors with highest HRs for the
prediction of 10-year risk of CV events (Table 4). Moreover, there were 598 subjects (11%)
with diabetes in our cohort (Table 1), in contrast to lower number in Framingham, making
our risk estimates in diabetic patients more reliably.
Fig 5. PARS charts for prediction of 10-year risk of fatal and non-fatal cardiovascular disease in ICS population with lower WHR
and CVD family history, 2001–2011.
https://doi.org/10.1371/journal.pone.0189389.g005
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While WHO [45] and the US National Heart, Lung and Blood Institute [46] recommend
the assessment of WC in people with a BMI of 250–349 kg/m2, the majority of generally used
CVD risk scores did not consider obesity measures (e.g. Framingham, SCORE, PROCAM),
but it was considered only by a few scores like QRISK [47, 48]. The INTERHEART study, a
large multinational retrospective study of acute myocardial infarction in 52 countries, reported
that WHR was three times more strongly related to the risk of acute myocardial infarction
than BMI [49]. However, these reports have not been tested in prospective studies. In our
model, high WHR was accounted for significant HR (1.31), and seems to be an important risk
factor in our population (Table 4). The inclusion of BMI and WC in our model or position of
WHR did not improve the model performance. Our findings in this large prospective study
support and expand those of the INTERHEART study, which includes data from Asian and
Middle Eastern countries, in addition to western data.
It was shown in the literature that the obesity prevalence is higher in developing countries,
compared with Asian countries [45]. These conclusions are mainly based on BMI values. How-
ever, if WHR is used to define obesity, such prevalence significantly increases, specifically in
the Middle East [49]. Furthermore, there is strong evidence that for a given WC, Asians have
higher levels of intra-abdominal adiposity, obesity-related metabolic consequences (dyslipide-
mia, insulin resistance, and diabetes) and mortality, compared to whites [50, 51]. It may partly
Fig 6. PARS charts for prediction of 10-year risk of fatal and non-fatal cardiovascular disease in ICS population with higher WHR
and CVD family history, 2001–2011.
https://doi.org/10.1371/journal.pone.0189389.g006
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justify why central obesity indices should be evaluated for CVD risk assessment in Asian and
Middle Eastern countries [51]. Unlike the majority of the current risk prediction models, our
data underscore the importance of WHR in the risk assessment and primary prevention of
CVD (Tables 1 and 4).
We used TC because it can be measured more easily and cost-effectively than HDL or LDL
cholesterol, and it is therefore measured more often in low-income and middle-income coun-
tries [10].
Our further analysis indicated other factors, including HDL-C, LDL-C, TC\HDL-C ratio,
high LDL-C, LDL-C\HDL-C ratio, TC\TG ratio, LDL-C\TG ratio, and the interaction term of
hypertriglyceridemia and low HDL-C, were relatively less important and were not associated
with performance improvement in either gender.
Because of the following considerations, caution should be taken when the inclusion criteria
of the present study are applied. (I) The study was based on the data from subjects with no
CVD, and the models should not be directly applied to subjects with CVD. (II) Similar to the
previous cohort studies worldwide [12], this study included individuals aged35 years and
therefore young adults were under-represented. Careful attention needs to be paid to the appli-
cation of data for young individuals. Moreover, our charts only estimate the risk of CV event
within a 10-year period.
The following ICS limitations must be considered: We underestimated the vascular diseases
because stable diseases, such as heart failure, and vascular dementia and also peripheral vascu-
lar diseases were not included. Although accurate clinical data obtained from the hospital,
the participants’ report of neurological symptoms was used to diagnose stroke when hospital
admission was not found in the medical records. Such a verbal history is probably not accurate
for CHD diagnosis [16]. Moreover, although the current study has distinctive coverage, in
comparison with other similar national studies, but the samples were limited to the central area
of Iran. Since, the estimated risk is dependent on the prevalence of the risk factors (Eq 1), there-
fore it is necessary for the proposed model to be externally validated, using other ethnic groups.
We speculate that PARS is likely to provide more appropriate estimates of CVD risk in the
contemporary Iranian population with suitable discrimination for those who are at high risk
in regard to age, sex, smoking status, diabetes, SBP, TC and WHR. PARS can serve as a useful
tool in developing future national guidelines for the primary prevention of CVD (Figs 3–6).
Furthermore, we anticipate that it could be applied in other countries in the EM region better
than the western risk assessment scores.
Preparing the online prediction tool and its mobile app were also considered. The program-
ming language used in PARS chart developed website was JavaScript and Bootstrap [52]. The
JavaScript programming language has been widely used, for web programming and general
purpose computing. The Android app was powered by Android Studio and API level 19 that
can be used for Android 4.2 or higher version [53]. The Android app and Web-based program
are freely accessible at www.prognosis.ir/PARS/index.php.
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